活化的重组因子Ⅶ给中医破血逐瘀法治疗急性脑出血带来的挑战和思考  

Thinking and Challenge Induced by the Hypothesis of Breaking Stagnant and Eliminating Blood Stasis in Treating Acute Cerebral Hemorrhage by rFⅦa

作　　者：郭建文[1] 蔡业峰[1] 杜宝新[1] 卢明[1] 张燕婷[1] 黄燕[1] 黄培新[1] 

机构地区：[1]广东省中医院神经一科,广州510120

出　　处：《中国中西医结合杂志》2005年第11期1027-1029,共3页Chinese Journal of Integrated Traditional and Western Medicine

基　　金：国家科技十五攻关项目(No.2001BA701A12b)

摘　　要：按照中医“离经之血便是瘀”的理论,用破血逐瘀法治疗急性脑出血(AICH)取得了确切的疗效,但没有关于超急期(发病0～4h)内中风证候演变自然史的资料。活化的重组因子Ⅶ(rFⅦa)经过多中心、随机、双盲的临床试验证明可以降低AICH的病死率和致残率,提示我们要重视超急期的止血治疗,同时在AICH发生的0～4h内慎用破血逐瘀药,可通过使用活血止血药和合理的药物配伍来消除加重出血的弊端。Deft according the TCM nite therapeutic effect has obtained by TCM in treating acute cerebral hemorrhage （ACH） theory of “blood circulating outside the vessels is the stasis” using breaking stagnant and eliminating blood stasis （Poxue Zhuyu） method, but no material involving the natural development of stoke in superacue stage （0 - 4hrs after onset of the disease） being presented so far. It has been proved by randomized, double-blinded multl-centeric clinical trials that recombinant activated factor Ⅶ （rFⅦa） could decreased the morbidity and disability of patients suffered from ACH, suggesting that use hemostasis treatment in ACH during superacu stage should be stressed, and the drugs for Poxue Zhuyu should be used cautiously in the period of 0- 4 hrs after onset. The hemorrhagic disorder could be eliminated by using drugs for Poxue Zhuyu and other medicines in rational combination.

关 键 词：急性脑出血 破血逐瘀 活化的重组因子Ⅶ 

分 类 号：R277.7[医药卫生—中医学]